No Stock Yet
Hainan Haiyao Unit's Minocycline Hydrochloride Capsules Passes Drug Regulator's Evaluation
04:55 AM EST, 03/08/2023 (MT Newswires) -- Haikou Pharmaceutical Factory, a unit of Hainan Haiyao (SHE:000566), received notification that minocycline hydrochloride capsules passed the consistency eva
Hainan Haiyao Unit Gets Regulatory Nod for Antibacterial Drug
02:33 AM EST, 01/31/2023 (MT Newswires) -- Haikou Pharmaceutical Factory, a subsidiary of Hainan Haiyao (SHE:000566), received approval from China's National Medical Products Administration for its ce
Hainan Haiyao Gets Regulatory Nod for Anti-Skin Disease Drug
05:12 AM EST, 01/09/2023 (MT Newswires) -- Hainan Haiyao (SHE:000566) unit Haikou Pharmaceutical Factory obtained regulatory approval for the registration of desloratadine oral solution drug. The drug
Plate changes | API industry ushered in block investment opportunities Pharmaceutical stocks pulled up
Zhitong Financial APP learned that on November 10, affected by the news of block investment opportunities in the API industry, A-share pharmaceutical stocks rose. As of the press release, 301089.SZ rose by more than 13%; Hainan Pharmaceutical (000566.SZ) rose by the daily limit; and stocks such as Fengyuan Pharmaceutical (000153.SZ), Hengrui Pharmaceutical (600276.SH), Hanyu Pharmaceutical (300199.SZ) and 600557.SH Pharmaceutical rose. On November 9, according to the website of the National Development and Reform Commission, the National Development and Reform Commission and the Ministry of Industry and Information Technology issued "on promoting the high quality of the API industry."
Hainan Haiyao Receives Letter of Concern: Request for Explanation of Specific Reasons for Higher Financial Expenses
Gelonhui, July 23 丨 Hainan Haiyao received a letter of concern. The exchange requested the company to explain the specific reasons for maintaining a high debt scale and bearing higher financial expenses when a large amount of money was retained on the books and there was no significant increase in operating income.
News flash: Hainan Haiyao dropped to 9.92 yuan and stopped reporting
Financial website, July 16 — Today, Hainan Haiyao opened at 10.97 yuan, ending at 09:35. The stock fell 9.98% to 9.92 yuan, ending at 9.95 yuan, ending the decline. Yesterday (2020/7-15), the stock had a net inflow of 688 million yuan, a net inflow of main players of 658 million yuan, a net inflow of 12.324,800 yuan from Chinese orders, and a net inflow of 18.264,800 yuan from retail investors. In the last month, Hainan Haiyao has been on the Dragon Tiger list a total of 2 times, indicating that Hainan Haiyao's stock is average. The company is mainly engaged in the import and export of proprietary Chinese and Western medicines, fine chemical products, chemical raw materials, health products, and those supporting the pharmaceutical industry
Analysis of strong sectors on the 15th: The hotel and catering sector rose sharply, and food and beverage stocks were active
On July 15, the stock indexes of the two markets maintained a weak and volatile trend in the intraday period. At the close, the Shanghai Index fell 1.56% to 3361.3 points, the Shenzhen Index fell 1.87% to 13734.13 points, and the GEM Index fell 1.6% to 2813.06 points. Looking at the market, the tourism, hotel and catering sectors have risen sharply, alcohol stocks have once again become active, and the food, beverage, and pharmaceutical sectors have strengthened. Specifically, the hotel, travel, hotel, food and tourism sectors have risen sharply intraday today. By the close, Hualin Tourism, Qujiang Cultural Tourism, Changbai Mountain, Yunnan Tourism, Xi'an Tourism, Zhangjiajie, Jiuhua Tourism, Dalian Shengya, Tianmu Lake, Huangshan Travel
Pharmaceutical stocks strengthened, Hainan Haiyao, Hepui, etc. rose and stopped
According to e-company news, pharmaceutical stocks strengthened, and Jiudian Pharmaceutical, Hainan Haiyao, and Hepuri rose and stopped, while the Tibetan pharmaceutical industry rose more than 9%.
Rise, stop, resume trading | Predictive performance increases, and pharmaceutical stocks are still divided collectively
(Market description) The two markets adjusted today. Near the end of the session, the index rebounded. Individual stocks in the two markets diverged, and nearly 20 stocks fell to a standstill. The short-term mood in the market was poor, and the willingness to sell in profit markets was strong. In terms of the sector, high-ranking sectors weakened sharply. The tax-free and semiconductor sectors once led the decline. Many high-ranking stocks such as Caesar Travel, Zhende Healthcare, and Guangbai Co., Ltd. fell to a standstill. In the afternoon, core stocks such as Huatian Technology and Shanghai Silicon Industry led a rebound in the semiconductor sector. The GEM index rebounded, and sectors such as agricultural cultivation, water conservancy, brokerage firms, coal and other sectors rose one after another. Looking at the overall situation, the return to high profit markets put a lot of pressure on the market, but market carrying performance was strong, and capital rotated rapidly.
Afternoon Review|Collective Index Adjustment Market Earning Effect Declines, Net Outflow of Main Capital of 78 billion dollars
On Tuesday, the stock indexes of the two markets fell collectively, the Shanghai index fell back to 3,400 points, and the GEM index fell below the 5-day EMA. By the midday closing, the Shanghai Index reported 3405.30 points, a decrease of 1.10%, the Shenzhen Index reported 13911.49 points, a decrease of 1.68%, and the GEM index reported 2832.87 points, a decrease of 1.96%. The two markets traded a total of 1082.9 billion yuan in the morning, an increase of 96.4 billion yuan over the same period yesterday. There was a net outflow of capital from Northbound Capital of 11.395 billion yuan in half a day, including a net outflow of 3.488 billion yuan from Shanghai Stock Connect and a net outflow of 7.907 billion yuan from Shenzhen Stock Connect. In terms of sectors, the increase in the bus, defense, military, and biological products sectors depended on
No Stock Yet